Lumacaftor/ Ivacaftor improves exercise tolerance in patients with Cystic Fibrosis and severe airflow obstruction

Treatment of patients with Cystic Fibrosis homozygous for the Phe508del gene, with Lumacaftor /Ivacaftor (LUM/IVA) improves outcomes in patients with FEV1  > 40% predicted. We set out to observe the most sensitive...

Source: BMC Pulmonary Medicine - June 17, 2019 Category: Respiratory Medicine Authors: Peter A. B. Wark, Kim Cookson, Theeba Thiruchelvam, John Brannan and Douglas J. Dorahy Tags: Research article Source Type: research